Literature DB >> 8964903

Blood-brain barrier breakdown and increased intercellular adhesion molecule (ICAM-1/CD54) expression after Semliki Forest (A7) virus infection facilitates the development of experimental allergic encephalomyelitis.

J P Erälinna1, M Soilu-Hänninen, M Röyttä, V Hukkanen, A A Salmi, R Salonen.   

Abstract

This report describes two mechanisms by which virus infection can facilitate demyelinating autoimmune inflammation in the murine CNS. In the BALB/c mouse model of experimental allergic encephalomyelitis (EAE), peripheral infection with an avirulent strain (A7) of Semliki Forest virus (SFV) increased the morbidity to EAE by infecting endothelial cells and damaging the blood-brain barrier (BBB). An influx of hematogenous CD18+ (LFA-1+ and MAC-1+) cells into the CNS compartment was followed by a local increase in intercellular adhesion molecule 1 (ICAM-1) expression on the vascular endothelium. Although SFV A7 infection without EAE induction caused multifocal cerebral vascular endothelial cell infection and BBB damage followed by cellular infiltration and transient increase of ICAM-1, inflammation and demyelination of CNS white matter with classical clinical signs of EAE was observed only in EAE-induced BALB/c mice, whereas the control mice remained neurologically healthy. The upregulation of ICAM-1 after virus infection was detected after the CD18+ (LFA-1+ and MAC-1+) cells had infiltrated the CNS both after EAE induction and also in nonsensitized control mice. The observed increase in ICAM-1 expression was transient in nonsensitized SFV A7 infected mice just as in the cellular infiltrates in the CNS, but EAE induction resulted in prolongation in both the cellular infiltrates and upregulation of ICAM-1. Thus, SFV A7 infection causes BBB damage and prolongs increased ICAM-1 expression on brain endothelium. This results in increased and more rapid morbidity to EAE in mice which have been sensitized with neuroantigen. However, SFV A7-infected mice without neuroantigen sensitization remain neurologically healthy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8964903     DOI: 10.1016/0165-5728(96)00031-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  7 in total

1.  Immunopathogenesis of alphaviruses.

Authors:  Victoria K Baxter; Mark T Heise
Journal:  Adv Virus Res       Date:  2020-07-08       Impact factor: 9.937

2.  Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice.

Authors:  Aaron L Olsen; John D Morrey; Donald F Smee; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-12-20       Impact factor: 5.970

Review 3.  Immune modulation by estrogens: role in CNS HIV-1 infection.

Authors:  Melinda E Wilson; Filomena O Dimayuga; Janelle L Reed; Thomas E Curry; Carol F Anderson; Avindra Nath; Annadora J Bruce-Keller
Journal:  Endocrine       Date:  2006-04       Impact factor: 3.633

4.  Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Inderjit Singh; Avtar K Singh
Journal:  Exp Neurol       Date:  2008-08-07       Impact factor: 5.330

5.  Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.

Authors:  Ajaib S Paintlia; Manjeet K Paintlia; Inderjit Singh; Robert B Skoff; Avtar K Singh
Journal:  Glia       Date:  2009-01-15       Impact factor: 7.452

6.  Neuroimmunological blood brain barrier opening in experimental cerebral malaria.

Authors:  Adela Nacer; Alexandru Movila; Kerstin Baer; Sebastian A Mikolajczak; Stefan H I Kappe; Ute Frevert
Journal:  PLoS Pathog       Date:  2012-10-25       Impact factor: 6.823

7.  Ly6c+ "inflammatory monocytes" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis.

Authors:  Daniel R Getts; Rachael L Terry; Meghann Teague Getts; Marcus Müller; Sabita Rana; Bimmi Shrestha; Jane Radford; Nico Van Rooijen; Iain L Campbell; Nicholas J C King
Journal:  J Exp Med       Date:  2008-09-08       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.